查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
寡核苷酸 CDMO 市场按服务类型、类型、应用、最终用户和地区划分 - 预测至 2029 年
市场调查报告书
商品编码
1643543

寡核苷酸 CDMO 市场按服务类型、类型、应用、最终用户和地区划分 - 预测至 2029 年

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 255 Pages | 订单完成后即时交付

价格

全球寡核苷酸 CDMO 市场规模预计将从 2024 年的 25.1 亿美元成长到 2029 年的 67.3 亿美元，预测期内的复合年增长率为 21.8%。

推动市场成长的关键因素包括更重视推出新型寡核苷酸药物，以及增加对 CDMO 的外包。寡核苷酸，例如反义寡核苷酸 (ASO)、小干扰 RNA (siRNA) 和适体，由于这些药物具有特异性和靶向作用而引起了人们的关注。这导致了开发活动的增加和 FDA 的连续核准。例如，2023年4月，Qalsody（tofersen）获得美国FDA核准，用于治疗与超氧化物歧化酶1（SOD1）基因突变有关的肌萎缩侧索硬化症（ALS）。此外，外包临床开发和製造（临床和商业）所需的专业知识和较低的成本进一步推动了该市场的成长。

研究范围
调查年份 2022-2029
基准年 2023
预测期 2024-2029
考虑单位 金额（美元）
按细分市场 按服务类型、按类型、按目的、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

2023 年，契约製造领域占据寡核苷酸 CDMO 市场的最大份额。随着寡核苷酸疗法需求的不断增长，CDMO 提供的专业知识可缩短生产时间并提高生产可扩展性等因素正在支持这一领域的成长。此外，CDMO 提供的监管专业知识可以进一步缩短产品上市时间和降低营运风险，这也是将製造外包外包给 CDMO 的另一个驱动因素。

製药和生物技术公司是寡核苷酸 CDMO 市场的主要终端用户群。寡核苷酸疗法的临床和商业性需求不断增加，推动製药和生物技术公司将生产委託给 CDMO。寡核苷酸的合成非常复杂，需要专业知识、高端技术和法规遵循。 CDMO已经建立了基础设施和系统来为这些公司提供服务。因此，製药和生技公司主要依赖 CDMO 进行製造、填充和其他服务。

包括中国、印度、日本和韩国在内的亚太地区，由于对寡核苷酸药物等创新治疗方法的关注度不断提高，生物製药产业正在快速成长。此外，由于人事费用、生产和营运成本低，亚太地区的 CDMO 服务具有显着的成本优势。这使得全球公司都愿意将他们的製造业务从亚太地区外包出去。

本报告研究了全球寡核苷酸 CDMO 市场，并根据服务类型、类型、应用、最终用户、区域趋势和公司概况对市场进行了详细分析。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章 市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/中断
  • 供应链分析
  • 价值链分析
  • 生态系分析
  • 技术分析
  • 定价分析
  • 2024-2025 年的重要会议与活动
  • 监管状态
  • 波特五力分析
  • 主要相关人员和采购标准
  • 主要购买标准
  • 投资金筹措场景
  • 人工智慧/生成式人工智慧对寡核苷酸 CDMO 市场的影响

6. 寡核苷酸 CDMO 市场（依服务种类）

  • 介绍
  • 契约製造
  • 合约开发
  • 其他的

7. 寡核苷酸 CDMO 市场（依类型）

  • 介绍
  • 反义寡核苷酸
  • 小干扰RNA
  • 其他的

8. 寡核苷酸 CDMO 市场（依应用）

  • 介绍
  • 治疗
  • 研究
  • 诊断

9. 寡核苷酸 CDMO 市场（以最终用户划分）

  • 介绍
  • 製药和生物技术公司
  • 诊断公司
  • 其他的

第 10 章寡核苷酸 CDMO 市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 韩国
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 医疗保健投资的增加和对个人化医疗的日益关注将推动市场
    • 中东宏观经济展望
    • 非洲宏观经济展望

第十一章 竞争格局

  • 概述
  • 主要参与企业的策略/优势
  • 2021-2023 年收益分析
  • 2023 年市场占有率分析
  • 公司估值矩阵：主要参与企业，2023 年
  • 公司估值矩阵：Start-Ups/中小企业，2023 年
  • 公司估值与财务指标
  • 品牌/服务比较
  • 竞争场景

第十二章 公司简介

  • 主要参与企业
    • BACHEM
    • THERMO FISHER SCIENTIFIC INC.
    • AGILENT TECHNOLOGIES, INC.
    • WUXI APPTEC
    • MARAVAI LIFESCIENCES
    • LONZA
    • EUROFINS SCIENTIFIC
    • DANAHER CORPORATION
    • GENSCRIPT
    • SYNGENE INTERNATIONAL LIMITED
    • EUROAPI
    • AJINOMOTO CO., INC.
    • ST PHARM
    • KANEKA CORPORATION
    • POLYPEPTIDE GROUP
    • AURIGENE PHARMACEUTICAL SERVICES LTD.
    • BIOSPRING
  • 其他公司
    • OLIGO FACTORY
    • CORDEN PHARMA
    • LGC BIOSEARCH TECHNOLOGIES
    • BI0-SYNTHESIS, INC.
    • MICROSYNTH
    • SYNOLIGO BIOTECHNOLOGIES, INC.
    • HONGENE BIOTECH CORPORATION
    • SYLENTIS, SA
    • CREATIVE BIOGENE

第十三章 附录

Product Code: BT 9273

The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8% during the forecast period. Key factors driving market growth include increasing focus on the launch of novel oligo-based drugs and growing outsourcing to CDMOs. Oligonucleotides, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, are being focused on due to the specificity and targeted action offered by these drugs. This has led to an increase in development activity followed by FDA approvals. For instance, in April 2023, Qalsody (tofersen) was approved by the US FDA for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Additionally, expertise and lower costs incurred while outsourcing clinical development and manufacturing (clinical and commercial) further support the growth of this market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Service type, Type, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The contract manufacturing segment accounted for the largest share in the oligonucleotide CDMO market, by service type, in 2023"

In 2023, contract manufacturing segment accounted for the largest share of the oligonucleotide CDMO market. Factors such as expertise offered by CDMOs leading to the reduction in production timelines and improving production scalability, supported by an increase in the demand for oligonucleotide therapeutics are supporting the growth of this segment. Additionally, regulatory expertise offered by CDMOs further reduces time-to-market and operational risks is another factor driving the outsourcing of manufacturing to CDMOs.

"The pharmaceutical and biotechnology companies end-user segment registered the highest growth rate and largest market share in the oligonucleotide CDMO market, by end user, during the forecast period"

Pharmaceutical and biotechnology companies are major end user segments of the oligonucleotide CDMO market. The increasing clinical and commercial demand for oligo-based therapies drives pharma and biotech companies to engage CDMOs for production. Oligonucleotide synthesis is complex and requires specialized expertise, high-end technologies, and regulatory compliance. CDMOs have established infrastructure and systems in place for offering to these companies. Thus, pharmaceutical and biotechnology companies largely rely on CDMOs, mainly for manufacturing, fill-finish, and other services.

"Asia Pacific: The fastest growing region in the oligonucleotide CDMO market"

Asia Pacific region, with countries like China, India, Japan, and South Korea are experiencing rapid growth in their biopharmaceutical industries, with increased focus on innovative therapies such as oligonucleotide-based drugs. Additionally, the Asia Pacific region offers significant cost advantages for CDMO services due to lower labor, production, and operational costs. This is attracting global players to outsource manufacturing activities from the Asia Pacific region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Supply Side - 65% and Demand Side - 35%
  • By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa - 5%

List of Companies Profiled in the Report:

  • Bachem (Switzerland)
  • Thermo Fisher Scientific Inc. (US)
  • Agilent Technologies, Inc. (US)
  • Maravai Lifesciences (US)
  • GenScript (US)
  • Wuxi Apptec (China)
  • Eurofins Scientific (Luxembourg)
  • Lonza (Switzerland)
  • Danaher Corporation (US)
  • Syngene International Limited (US)
  • EUROAPI (France)
  • Ajinomoto Co., Inc. (Japan)
  • ST Pharm (South Korea)
  • Kaneka Corporation (Japan)
  • Aurigene Pharmaceutical Services Ltd. (India)
  • PolyPeptide Group (Switzerland)
  • Biospring (Germany)
  • Oligo factory (US)
  • Corden Pharma (Switzerland)
  • LGC Biosearch Technologies (UK)
  • Bio-Synthesis Inc (US)
  • Microsynth (Switzerland)
  • Synoligo Biotechnologies, Inc. (US)
  • Hongene Biotech Corporation (China)
  • Sylentis, S.A. (Spain)
  • Creative Biogene. (US)

Research Coverage:

This report provides a detailed picture of the global oligonucleotide CDMO Market. It aims to estimate the size and future growth potential of the market across different segments such as service type, stage, type, application, end users and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide CDMO market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the oligonucleotide CDMO market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall oligonucleotide CDMO market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Growing focus on development and commercialization of oligo-based therapeutics), restraints (Complexities associated with oligonucleotide manufacturing ), opportunities (Increasing use of oligos for CRISPR/Cas 9 application), and challenges (Lack of sustainable and eco-friendly supply chain) influencing the growth of the oligonucleotide CDMO market.
  • Innovation: Detailed insights on upcoming technologies, research & development activities, in the oligonucleotide CDMO market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide CDMO market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the oligonucleotide CDMO market like- Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), EUROAPI (France), ST Pharm (South Korea), Wuxi Apptec (China), Maravai Lifesciences (US), and Biospring (Germany) among others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED & REGIONS CONSIDERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
  • 4.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE & COUNTRY (2023)
  • 4.3 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS 2029
  • 4.4 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024 VS 2029
  • 4.5 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY END USER, 2023
  • 4.6 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing focus on development and commercialization of oligo-based therapeutics
      • 5.2.1.2 Advantages of contract development and manufacturing
      • 5.2.1.3 Increasing focus on precision/personalized medicine
      • 5.2.1.4 Technological advancements
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of sustainable and eco-friendly supply chain
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • 5.6.1 ROLE IN ECOSYSTEM
  • 5.7 TECHNOLOGY ANALYSIS
    • 5.7.1 KEY TECHNOLOGIES
      • 5.7.1.1 Process technologies
        • 5.7.1.1.1 Solid-phase synthesis
        • 5.7.1.1.2 Liquid-phase synthesis
        • 5.7.1.1.3 Enzymatic oligo synthesis
    • 5.7.2 COMPLEMENTARY TECHNOLOGIES
      • 5.7.2.1 Purification, analysis, and quality control technologies
        • 5.7.2.1.1 Chromatography
        • 5.7.2.1.2 Mass spectrometry
      • 5.7.2.2 Other technologies
        • 5.7.2.2.1 Polymerase chain reaction (PCR)
        • 5.7.2.2.2 Next-generation sequencing
    • 5.7.3 ADJACENT TECHNOLOGIES
      • 5.7.3.1 3D printing
  • 5.8 PRICING ANALYSIS
    • 5.8.1 INDICATIVE PRICE OF OLIGONUCLEOTIDE CDMO SERVICES, BY KEY PLAYER
    • 5.8.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE)
  • 5.9 KEY CONFERENCES & EVENTS IN 2024-2025
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY FRAMEWORK
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 DEGREE OF COMPETITION
    • 5.11.2 BARGAINING POWER OF SUPPLIERS
    • 5.11.3 BARGAINING POWER OF BUYERS
    • 5.11.4 THREAT OF SUBSTITUTES
    • 5.11.5 THREAT OF NEW ENTRANTS
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE CDMO SERVICES
  • 5.13 KEY BUYING CRITERIA
  • 5.14 INVESTMENT & FUNDING SCENARIO
  • 5.15 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET

6 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE

  • 6.1 INTRODUCTION
  • 6.2 CONTRACT MANUFACTURING
    • 6.2.1 COMMERCIAL STAGE
      • 6.2.1.1 Flexible, scalable production facilities to propel market growth
    • 6.2.2 CLINICAL STAGE
      • 6.2.2.1 Growing demand for oligonucleotide-based therapeutics to drive market
  • 6.3 CONTRACT DEVELOPMENT
    • 6.3.1 GROWING FOCUS ON REDUCING MANUFACTURING RISKS TO SUPPORT MARKET GROWTH
  • 6.4 OTHER SERVICES

7 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 ANTISENSE OLIGONUCLEOTIDES
    • 7.2.1 SPECIFIC DEVELOPMENT & MANUFACTURING REQUIREMENTS WELL-SUPPORTED BY CDMOS TO DRIVE MARKET GROWTH
  • 7.3 SMALL INTERFERING RNA
    • 7.3.1 POTENTIAL IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
  • 7.4 OTHER OLIGONUCLEOTIDES

8 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 THERAPEUTIC APPLICATIONS
    • 8.2.1 GROWING DEMAND FOR OLIGONUCLEOTIDE-BASED THERAPEUTICS TO DRIVE MARKET GROWTH
  • 8.3 RESEARCH APPLICATIONS
    • 8.3.1 USE OF OLIGOS IN SEQUENCING FOR ADVANCING DRUG DEVELOPMENT TO SUPPORT GROWTH
  • 8.4 DIAGNOSTIC APPLICATIONS
    • 8.4.1 GROWING APPLICATIONS IN MOLECULAR DIAGNOSTICS AND IVD TO PROPEL MARKET

9 OLIGONUCLEOTIDE CDMO MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 INCREASED INVESTMENTS IN OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT MARKET GROWTH
  • 9.3 DIAGNOSTIC COMPANIES
    • 9.3.1 GROWTH OF PERSONALIZED DIAGNOSTICS TO PROPEL MARKET
  • 9.4 OTHER END USERS

10 OLIGONUCLEOTIDE CDMO MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Rising approvals of oligonucleotide-based drugs to support market growth
    • 10.2.3 CANADA
      • 10.2.3.1 Government initiatives to drive market growth in Canada
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Academic-industry collaborations to drive market
    • 10.3.3 UK
      • 10.3.3.1 Strategic investments in biomanufacturing to boost market growth
    • 10.3.4 FRANCE
      • 10.3.4.1 Focus on advanced biologics manufacturing to drive market
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing focus on biotechnology innovation to boost market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Strategic investments in biotechnology to support market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Government-backed Initiatives and expansion of major companies to strengthen biotechnology sector in China
    • 10.4.3 JAPAN
      • 10.4.3.1 Increased investment in oligonucleotide research and manufacturing to boost market
    • 10.4.4 INDIA
      • 10.4.4.1 Rapidly expanding biopharma ecosystem to drive market
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Robust government support to expand oligonucleotide CDMO sector
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Strong research institutions and growing collaboration between academia and industry to support market growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Rapidly advancing pharmaceutical and biotechnology sectors to fuel growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 RISING INVESTMENTS IN HEALTHCARE AND GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 10.6.3 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET
  • 11.3 REVENUE ANALYSIS, 2021-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Service type footprint
      • 11.5.5.4 Type footprint
      • 11.5.5.5 Application footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING
      • 11.6.5.1 Detailed list of key startups/SMES
      • 11.6.5.2 Competitive benchmarking of startups/SMEs
  • 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.8 BRAND/SERVICE COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 DEALS
    • 11.9.2 EXPANSIONS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 BACHEM
      • 12.1.1.1 Business overview
      • 12.1.1.2 Services offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 THERMO FISHER SCIENTIFIC INC.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Services offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Deals
        • 12.1.2.3.2 Expansions
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 AGILENT TECHNOLOGIES, INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Services offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Deals
        • 12.1.3.3.2 Expansions
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 WUXI APPTEC
      • 12.1.4.1 Business overview
      • 12.1.4.2 Services offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Expansions
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices made
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 MARAVAI LIFESCIENCES
      • 12.1.5.1 Business overview
      • 12.1.5.2 Services offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Deals
    • 12.1.6 LONZA
      • 12.1.6.1 Business overview
      • 12.1.6.2 Services offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Deals
        • 12.1.6.3.2 Expansions
    • 12.1.7 EUROFINS SCIENTIFIC
      • 12.1.7.1 Business overview
      • 12.1.7.2 Services offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
        • 12.1.7.3.2 Expansions
    • 12.1.8 DANAHER CORPORATION
      • 12.1.8.1 Business overview
      • 12.1.8.2 Services offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Expansions
    • 12.1.9 GENSCRIPT
      • 12.1.9.1 Business overview
      • 12.1.9.2 Services offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Expansions
    • 12.1.10 SYNGENE INTERNATIONAL LIMITED
      • 12.1.10.1 Business overview
      • 12.1.10.2 Services offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Expansions
    • 12.1.11 EUROAPI
      • 12.1.11.1 Business overview
      • 12.1.11.2 Services offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Deals
        • 12.1.11.3.2 Expansions
    • 12.1.12 AJINOMOTO CO., INC.
      • 12.1.12.1 Business overview
      • 12.1.12.2 Services offered
    • 12.1.13 ST PHARM
      • 12.1.13.1 Business overview
      • 12.1.13.2 Services offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Expansions
        • 12.1.13.3.2 Other developments
    • 12.1.14 KANEKA CORPORATION
      • 12.1.14.1 Business overview
      • 12.1.14.2 Services offered
    • 12.1.15 POLYPEPTIDE GROUP
      • 12.1.15.1 Business overview
      • 12.1.15.2 Services offered
      • 12.1.15.3 Recent developments
        • 12.1.15.3.1 Deals
    • 12.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
      • 12.1.16.1 Business overview
      • 12.1.16.2 Services offered
    • 12.1.17 BIOSPRING
      • 12.1.17.1 Business overview
      • 12.1.17.2 Services offered
      • 12.1.17.3 Recent developments
        • 12.1.17.3.1 Service approvals
        • 12.1.17.3.2 Expansions
  • 12.2 OTHER PLAYERS
    • 12.2.1 OLIGO FACTORY
    • 12.2.2 CORDEN PHARMA
    • 12.2.3 LGC BIOSEARCH TECHNOLOGIES
    • 12.2.4 BI0-SYNTHESIS, INC.
    • 12.2.5 MICROSYNTH
    • 12.2.6 SYNOLIGO BIOTECHNOLOGIES, INC.
    • 12.2.7 HONGENE BIOTECH CORPORATION
    • 12.2.8 SYLENTIS, S.A.
    • 12.2.9 CREATIVE BIOGENE

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 OLIGONUCLEOTIDE CDMO MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: IMPACT ANALYSIS
  • TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2023)
  • TABLE 5 INDICATIVE PRICE OF OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES, BY KEY PLAYER
  • TABLE 6 OLIGONUCLEOTIDE CDMO MARKET: LIST OF CONFERENCES & EVENTS
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 OLIGONUCLEOTIDE CDMO MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF OLIGONUCLEOTIDE CDMO SERVICES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • TABLE 14 BUYING CRITERIA FOR OLIGONUCLEOTIDE CDMO MARKET, BY END USER
  • TABLE 15 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 16 OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 17 OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 18 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 19 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 20 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 21 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 EUROPE: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 LATIN AMERICA: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 28 NORTH AMERICA: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 EUROPE: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 LATIN AMERICA: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 EUROPE: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 38 NORTH AMERICA: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 EUROPE: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 LATIN AMERICA: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 43 OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 44 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 59 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 60 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 75 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 92 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 98 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 99 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 100 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 101 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 103 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 104 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 105 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 106 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 107 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: KEY MACROINDICATORS
  • TABLE 109 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 112 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 113 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 115 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 116 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 117 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 118 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 120 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 121 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 122 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 123 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 124 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 125 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 126 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 127 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 128 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 129 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 130 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 132 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 133 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 134 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 135 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 136 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 137 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 138 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 139 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 140 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 141 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 142 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 143 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 146 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 152 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 153 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 154 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 155 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 156 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 157 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 159 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 160 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 162 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 163 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 164 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 165 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 166 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 167 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 168 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 169 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 170 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 172 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 174 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 175 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 176 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 177 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 178 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 179 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 181 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 182 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 184 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 185 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 186 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 187 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 189 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 190 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 191 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 192 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 194 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 195 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 196 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 197 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 199 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 200 AFRICA: KEY MACROINDICATORS
  • TABLE 201 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022-2029 (USD MILLION)
  • TABLE 203 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 204 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 205 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 206 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS DEPLOYED BY KEY CDMOS, JANUARY 2021-DECEMBER 2024
  • TABLE 207 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION
  • TABLE 208 OLIGONUCLEOTIDE CDMO MARKET: REGION FOOTPRINT
  • TABLE 209 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT
  • TABLE 210 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT
  • TABLE 211 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT
  • TABLE 212 OLIGONUCLEOTIDE CDMO MARKET: DETAILED LIST OF KEY STARTUP/SMES
  • TABLE 213 OLIGONUCLEOTIDE CDMO MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 214 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 215 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 216 BACHEM: COMPANY OVERVIEW
  • TABLE 217 BACHEM: SERVICES OFFERED
  • TABLE 218 BACHEM: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 219 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 220 THERMO FISHER SCIENTIFIC: SERVICES OFFERED
  • TABLE 221 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 222 THERMO FISHER SCIENTIFIC: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 223 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 224 AGILENT TECHNOLOGIES: SERVICES OFFERED
  • TABLE 225 AGILENT TECHNOLOGIES: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 226 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 227 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 228 WUXI APPTEC: SERVICES OFFERED
  • TABLE 229 WUXI APPTEC: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 230 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 231 MARAVAI LIFESCIENCES: SERVICES OFFERED
  • TABLE 232 MARAVAI LIFESCIENCES: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 233 LONZA: COMPANY OVERVIEW
  • TABLE 234 LONZA: SERVICES OFFERED
  • TABLE 235 LONZA: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 236 LONZA: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 237 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 238 EUROFINS SCIENTIFIC: SERVICES OFFERED
  • TABLE 239 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 240 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 241 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 242 DANAHER CORPORATION: SERVICES OFFERED
  • TABLE 243 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 244 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 245 GENSCRIPT: SERVICES OFFERED
  • TABLE 246 GENSCRIPT: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 247 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 248 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
  • TABLE 249 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 250 EUROAPI: COMPANY OVERVIEW
  • TABLE 251 EUROAPI: SERVICE OFFERED
  • TABLE 252 EUROAPI: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 253 EUROAPI: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 254 AJINOMOTO: COMPANY OVERVIEW
  • TABLE 255 AJINOMOTO: SERVICES OFFERED
  • TABLE 256 ST PHARM: COMPANY OVERVIEW
  • TABLE 257 ST PHARM: SERVICES OFFERED
  • TABLE 258 ST PHARM: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 259 ST PHARM: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 260 KANEKA CORPORATION: COMPANY OVERVIEW
  • TABLE 261 KANEKA CORPORATION: SERVICES OFFERED
  • TABLE 262 POLYPEPTIDE GROUP: COMPANY OVERVIEW
  • TABLE 263 POLYPEPTIDE GROUP: SERVICES OFFERED
  • TABLE 264 POLYPEPTIDE GROUP: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 265 AURIGENE PHARMACEUTICAL SERVICES: COMPANY OVERVIEW
  • TABLE 266 AURIGENE PHARMACEUTICAL SERVICES: SERVICES OFFERED
  • TABLE 267 BIOSPRING: COMPANY OVERVIEW
  • TABLE 268 BIOSPRING: SERVICES OFFERED
  • TABLE 269 BIOSPRING: SERVICE APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 270 BIOSPRING: EXPANSIONS, JANUARY 2021-DECEMBER 2024

List of Figures

  • FIGURE 1 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARIES: OLIGONUCLEOTIDE CDMO MARKET
  • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF BACHEM: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 17 GROWING FOCUS ON DEVELOPMENT AND COMMERCIALIZATION OF OLIGO-BASED THERAPEUTICS-A KEY FACTOR DRIVING GROWTH
  • FIGURE 18 CONTRACT MANUFACTURING ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN OLIGONUCLEOTIDE CDMO MARKET IN 2023
  • FIGURE 19 ANTISENSE OLIGONUCLEOTIDES SEGMENT TO DOMINATE MARKET TILL 2029
  • FIGURE 20 THERAPEUTIC APPLICATIONS TO HOLD LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD
  • FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES HELD LARGEST SHARE OF END-USER MARKET IN 2023
  • FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 23 OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE CDMOS
  • FIGURE 25 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  • FIGURE 26 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 27 OLIGONUCLEOTIDE CDMO SERVICES MARKET ECOSYSTEM
  • FIGURE 28 OLIGONUCLEOTIDE CDMO MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES (PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES)
  • FIGURE 30 BUYING CRITERIA OF END USERS
  • FIGURE 31 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
  • FIGURE 32 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
  • FIGURE 34 OLIGONUCLEOTIDE CDMO MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
  • FIGURE 35 OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 36 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT
  • FIGURE 38 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 39 OLIGONUCLEOTIDE CDMO MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 40 OLIGONUCLEOTIDE CDMO MARKET: EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 41 OLIGONUCLEOTIDE CDMO MARKET: BRAND/SERVICE COMPARISON MATRIX
  • FIGURE 42 BACHEM: COMPANY SNAPSHOT (2023)
  • FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2023)
  • FIGURE 44 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2023)
  • FIGURE 45 WUXI APPTEC: COMPANY SNAPSHOT (2023)
  • FIGURE 46 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2023)
  • FIGURE 47 LONZA: COMPANY SNAPSHOT (2023)
  • FIGURE 48 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
  • FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 50 GENSCRIPT: COMPANY SNAPSHOT (2023)
  • FIGURE 51 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023)
  • FIGURE 52 EUROAPI: COMPANY SNAPSHOT (2023)
  • FIGURE 53 AJINOMOTO: COMPANY SNAPSHOT (2023)
  • FIGURE 54 ST PHARM: COMPANY SNAPSHOT (2023)
  • FIGURE 55 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 56 POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2023)